A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2

Despite substantial advances in the treatment of acute myeloid leukemia (AML), only 30% of patients survive more than 5 years. Therefore, new therapeutics are much needed. Here, we present a novel therapeutic strategy targeting PR1, an HLA-A2 restricted myeloid leukemia antigen. Previously, we have...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Immunol
Auteurs principaux: Herrmann, Amanda C., Im, Jin S., Pareek, Sumedha, Ruiz-Vasquez, Wilfredo, Lu, Sijie, Sergeeva, Anna, Mehrens, Jennifer, He, Hong, Alatrash, Gheath, Sukhumalchandra, Pariya, St. John, Lisa, Clise-Dwyer, Karen, Zha, Dongxing, Molldrem, Jeffrey J.
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2019
Sujets:
Immunology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6345694/
https://ncbi.nlm.nih.gov/pubmed/30713535
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.03153
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires